I am a
Home I AM A Search Login

Papers of the Week

2022 Apr 20

J Hepatol

Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.


Yuen M-F, Agarwal K, Ma X, Nguyen TT, Schiff ER, Hann H-WL, Dieterich DT, Nahass RG, Park JS, Chan S, Han S-HB, Gane EJ, Bennett M, Alves K, Evanchik M, Yan R, Huang Q, Lopatin U, Colonno R, Ma J, et al.
J Hepatol. 2022 Apr 20.
PMID: 35460726.


Hepatitis B virus (HBV) nucleos(t)ide reverse transcriptase inhibitors (NrtI) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppression when combined with NrtIs. This phase 2 trial (NCT03576066) evaluated the efficacy and safety of the investigational core inhibitor, vebicorvir (VBR), in virologically-suppressed patients on NrtI.